Overview

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Status:
Unknown status

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

This study will investigate the efficacy and tolerability of a short (6 months) high dose therapy followed by a standard dose compared to a continuous treatment with a standard dose of imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.

Phase:

Phase 3

Details

Lead Sponsor:

Central European Leukemia Study Group

Treatments:

Imatinib Mesylate